Ammonium bromide 400mg/5ml / Potassium bromide 400mg/5ml / Sodium bromide 400mg/5ml oral solution
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Ammonium bromide + Potassium bromide + Sodium bromide
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
1950–2026
Showing the 50 most relevant studies, sorted by most relevant.
Toshiaki Isono
Journal of Chemical & Engineering Data, 1984
Kashinath R. Patil, Atri D. Tripathi, Gopal Pathak, et al.
Journal of Chemical & Engineering Data, 1991
H. Kise, H. Ogata
Journal of Polymer Science Part A, 1983
E. L. Wagner, D. F. Hornig
The Journal of Chemical Physics, 1950
Bennekou SH, Allende A, Bearth A, et al.
2025
The European Commission mandated EFSA to assess the toxicity of bromide, the existing maximum residue levels (MRLs), and possible transfer from feed into food of animal origin. The critical effects of bromide in experimental animals are on the thyroid and central nervous system. Changes in thyroid hormone homeostasis could result in neurodevelopmental toxicity, among other adverse effects. Changes in thyroid hormone concentrations and neurophysiological parameters have also been observed in experimental human studies, but the evidence was limited. Dose-response modelling of decreased blood thyroxine concentrations in rats resulted in a reference point of 40 mg/kg body weight (bw) per day. The Scientific Committee established a tolerable daily intake (TDI) of 0.4 mg/kg bw per day and an acute reference dose (ARfD) of 0.4 mg/kg bw per day to protect against adverse neurodevelopmental effects. The TDI value is supported by the results of experimental human studies with a NOAEL of 4 mg/kg bw per day and 10-fold interindividual variability. The TDI and ARfD are considered as conservative with 90% certainty. Insufficient evidence related to the toxicological effects of bromide was available for animals, with the exception of dogs. Therefore, the reference point of 40 mg/kg bw per day was extrapolated to maximum safe concentrations of bromide in complete feed for other animal species. Bromide can transfer from feed to food of animal origin, but, from the limited data, it was not possible to quantify the transfer rate. Monitoring data exceeded the current MRLs for some food commodities, generally with a low frequency. A conservative safety screening of the MRLs indicated that the TDI and ARfD are exceeded for some EU diets. Dietary exposure assessment for animals was not feasible due to insufficient data. The Scientific Committee recommends data be generated to allow robust dietary exposure assessments in the future, and data that support the risk assessment.
Abstract licence: CC BY-ND
Piedra HF, Plaza M
2024
The first visible-light-induced protocol for the general preparation of alkenyl thiocyanates from alkenyl bromides is presented. The reaction is simple, proceeds under very mild conditions and demonstrates broad functional group tolerance. Additionally, a flow protocol was developed to enable efficient scale-up of alkenyl thiocyanate synthesis, further enhancing the practicality and value of the method. Importantly, these alkenyl thiocyanates serve as valuable building blocks for the construction of diverse families of sulfur-containing molecules through trifluoromethylations, cycloadditions, oxidations, and C-S or P-S bond forming reactions.
Abstract licence: CC BY-NC
G BA, Bhat RS, G MJ, et al.
2025
- Chromium Compounds
- Carbon
- Acetaminophen
The development of novel electrochemical sensors has attracted significant interest in detecting pharmaceutical compounds with high sensitivity and selectivity. Chromium oxide nanoparticles (Cr₂O₃ NPs) are promising materials for modifying carbon paste electrodes (CPEs) due to their excellent electrochemical properties and conductivity. The Cr2O3 NPs were synthesized by the combustion method using, chromium (III) nitrate and glycine at 350 ℃. The microstructure of the Cr2O3 NPs was examined using Field emission scanning electron microscopy (FESEM). The phase composition of the NPs was established using X-ray diffraction spectroscopy (XRD). Raman Spectroscopy focused on the crystallinity of the NPs. Energy dispersive X-ray spectroscopy (EDS) gives the elemental composition. The surface structure of the bare carbon paste electrode (BCPE), was modified with a Chromium oxide composite carbon paste electrode (CrCCPE), and then by the immobilization process of the addition of Cetyl trimethyl ammonium bromide (CTAB) on the electrode fabricated as CTAB modified Cr2O3 composite carbon paste electrode (CT-MCrCCPE) are confirmed by Scanning electron microscopy (SEM). The properties of the modified electrode (CT-MCrCCPE) were investigated for the detection of paracetamol (PA) in a phosphate buffer (PBS) at 6.5 pH using cyclic voltammetry (CV), Electrochemical impedance spectroscopy (EIS) and Differential pulse voltammetry (DPV). The diffusion control process was confirmed by the variation in scan rate (SR), and DPV analysis showed good detection limit (DL) and quantification limit (QL) found as 0.322µM and 1.076µM. PA detection showed selectivity even with interfering ions and achieved 95.37-99.33% accuracy in real sample analysis. CT-MCrCCPE reveals high catalytic activity, sensitivity, selectivity, repeatability, and reproducibility for paracetamol detection.
Abstract licence: CC BY-NC-ND
Gouveia D, Mandigers P, Cherubini GB
2024
Bromide is the first effective antiseizure medication used in human medicine since the XIX century. Initially met with skepticism, bromide quickly gained enthusiasm within the medical field until being largely replaced by newer antiseizure medications with significantly fewer adverse effects in people. In veterinary medicine, bromide continues to be used in the management of epileptic patients for over 30 years, yet adverse effects can impact owners and patients alike. We sought to provide the general practitioner and veterinary neurologist with insightful information on both the positive and negative attributes of bromide, explore factors that may influence its desirability as an antiseizure medication in specific veterinary cases and elucidate its current role in modern epilepsy treatment for veterinary patients. It's also our endeavor to discuss the current use as an alternative or add-on with other known antiseizure medications and potential future studies that might enhance our understanding and use of this medication.
Abstract licence: CC BY
Amoah E, Sahraeian T, Seth A, et al.
2024
- Oligosaccharides
- Spectrometry, Mass, Electrospray Ionization
- Tandem Mass Spectrometry
Oligosaccharides demonstrate many bioactivities with applications in the pharmaceutical, cosmetic, and food industries. They also serve as biomarkers for various diseases including cancer and glycogen storage disorders. These make the structural characterization of oligosaccharides very important. Unfortunately, the structural diversity found in saccharides make their characterization challenging, necessitating the development of sophisticated instrumentation to enable isomer differentiation. Herein, we report the ability of halide (Cl- and Br-) adducts to enable direct differentiation of oligosaccharide isomers using conventional collision-induced dissociation (CID) tandem MS (MS/MS). The halide adducts were generated by direct infusion nano-electrospray ionization (nESI). For the first time, this traditional nESI CID MS/MS platform was used to differentiate stereoisomers of trisaccharides (cellotriose β(1 → 4) and maltotriose α(1 → 4), tetrasaccharides (cellotetraose and maltotetraose), and pentasaccharides (cellopentaose and maltopentaose)). In addition, the MS/MS of halide adducts enabled the differentiation of positional, structural, and linkage isomers from a total of 14 oligosaccharides. The isomer differentiation was realized by the generation of distinct diagnostic fragment ions in CID. We also performed principal component analysis using the entire range of MS/MS fragment ion profiles and found that negative-ion mode halide adduction provided more effective isomer differentiation compared with positive-ion mode sodium adduction. Finally, we demonstrated complex mixture analysis by spiking all 14 oligosaccharides into raw urine, of which we successfully distinguished species based on molecular weight (first dimension) and CID MS/MS fragmentation patterns as the second dimension separation. This work effectively showcases the potential to use direct infusion nESI-MS/MS to characterize synthetic oligosaccharide isomers in unpurified reaction mixture as well as from biofluids for diagnostic purposes.
Abstract licence: CC BY-NC
Yu J, Liu J, Liu Y, et al.
2025
Developing multifunctional wound dressings with excellent mechanical properties, strong tissue adhesion, and efficient antibacterial activity is crucial for promoting wound healing. This study prepared a novel nanocomposite hydrogel dressing based on sodium alginate-polyacrylic acid dual crosslinking networks, incorporating tannic acid-coated cellulose nanocrystals (TA@CNC) and in-situ reduced silver nanoparticles for multifunctional enhancement. The rigid CNC framework significantly improved mechanical properties (elastic modulus of 146 kPa at 1 wt%), while TA catechol groups provided excellent adhesion (36.4 kPa to pigskin, 122% improvement over pure system) through dynamic hydrogen bonding and coordination interactions. TA served as a green reducing agent for uniform AgNPs loading, with CNC negative charges preventing particle aggregation. Antibacterial studies revealed synergistic effects between TA-induced membrane disruption and Ag+-triggered reactive oxygen species generation, achieving >99.5% inhibition against Staphylococcus aureus and Escherichia coli. The TA@CNC-regulated porous structure balanced swelling performance and water vapor transmission, facilitating wound exudate management and moist healing. This composite hydrogel successfully integrates mechanical toughness, tissue adhesion, antibacterial activity, and biocompatibility, providing a novel strategy for advanced wound dressing development.
Abstract licence: CC BY
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.